Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease
Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease
About this item
Full title
Author / Creator
SENSCIS Trial Investigators , Distler, Oliver , Highland, Kristin B , Gahlemann, Martina , Azuma, Arata , Fischer, Aryeh , Mayes, Maureen D , Raghu, Ganesh , Sauter, Wiebke , Girard, Mannaig , Alves, Margarida , Clerisme-Beaty, Emmanuelle , Stowasser, Susanne , Tetzlaff, Kay , Kuwana, Masataka and Maher, Toby M
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
Patients with interstitial lung disease associated with systemic sclerosis were treated with usual care plus placebo or nintedanib. The annual rate of change in forced vital capacity assessed over a 52-week period was −52.4 ml per year with nintedanib and −93.3 ml per year with placebo. There were no differences in other measures of systemic sclero...
Alternative Titles
Full title
Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2247765596
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2247765596
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1903076
